UCrest Berhad announced Further to the announcements made by the Company on the MOU between Company and Russian Direct Investment Fund on 9 April 2021, 14 April 2021, 28 April 2021, 19 May 2021 and 20 May 2021, the Board of Directors of UCrest announced that the Company has on 9 June 2021 entered into a MOU with an additional new contract manufacturer in China and secured the capacity to produce the Sputnik V vaccines of up to 100 million doses per year for 2 years. Depending on the dynamic of the pandemic, The company expects it will be likely to contribute positively to the net assets per share of UCrest group for the financial year ending 31 May 2022. UCrest does not foresee any exceptional risks other than pandemic risks, execution risks, political risks and country risks associated with the agreements. None of the Directors and/or major shareholders of UCrest or persons connected with them have any interests, direct or indirect, in the agreements.